E-LIB Suche - Ergebnisse für: Sharman, J. P.

1

A phase 2 study of zanubrutinib in previously treated B‐cel..:

Shadman, M. ; Burke, J. M. ; Zafar, S. F....
Hematological Oncology. 41 (2023) S2 - p. 469-471 , 2023

Link: https://doi.org/10.1002/..

2

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES ..:

Herrera, A. F. ; Tracy, S. ; Sehn, L. H....
Hematological Oncology. 41 (2023) S2 - p. 175-177 , 2023

Link: https://doi.org/10.1002/..

3

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (..:

Shadman, M. ; Flinn, I. W. ; Kingsley, E. C....
HemaSphere. 6 (2022) - p. 1769-1770 , 2022

Link: https://doi.org/10.1097/..

4

P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (..:

Lansigan, F. ; Andorsky, D. J. ; Coleman, M....
HemaSphere. 6 (2022) - p. 1043-1044 , 2022

Link: https://doi.org/10.1097/..

5

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STU..:

Sharman, J. P. ; Jurczak, W. ; Coombs, C. C....
HemaSphere. 6 (2022) - p. 1744-1745 , 2022

Link: https://doi.org/10.1097/..

6

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REV..:

Eyre, T. A. ; Wang, M. L. ; Shah, N. N....
HemaSphere. 6 (2022) - p. 991-992 , 2022

Link: https://doi.org/10.1097/..

7

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORA..:

Sharman, J. P. ; Egyed, M. ; Jurczak, W....
HemaSphere. 6 (2022) - p. 564-565 , 2022

Link: https://doi.org/10.1097/..

8

P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLAR..:

Song, Y. ; Jin, J. ; Tilly, H....
HemaSphere. 6 (2022) - p. 1078-1079 , 2022

Link: https://doi.org/10.1097/..

9

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUD..:

Eyre, T. A. ; Shah, N. N. ; Le Gouill, S....
HemaSphere. 6 (2022) - p. 990-991 , 2022

Link: https://doi.org/10.1097/..

10

INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAP..:

. Lansigan, F ; . Parameswaran, V ; . Yacoub, A...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

CN4 Patient-Reported Outcomes from the Phase 3, Randomized ..:

Walker, P. ; Sharman, J.P. ; Jurczak, W....
Value in Health. 24 (2021) - p. S3-S4 , 2021

Link: https://doi.org/10.1016/..

12

PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN..:

Shadman, M. ; Sharman, J. P. ; Levy, M. Y....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAP..:

Sharman, J. P. ; Melear, J. M. ; Yacoub, A....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

14

Antibody–drug conjugates for previously treated aggressive ..:

Burke, J. M. ; Morschhauser, F. ; Andorsky, D...
Expert Review of Clinical Pharmacology. 13 (2020) 10 - p. 1073-1083 , 2020

Link: https://doi.org/10.1080/..

15

PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB‐INTOLERANT PATI..:

Rogers, K.A. ; Thompson, P.A. ; Allan, J.N....
Hematological Oncology. 37 (2019) S2 - p. 60-61 , 2019

Link: https://doi.org/10.1002/..